The funding announcement for osimertinib is a breath of equity because it meets the greatest treatment need right now. Osimertinib is the gold standard for EGFR, stage 4, Non-Small Cell Lung Cancer (NSCLC) and it will be life changing for patients and their families. We want to acknowledge the leaders and clinical advisors at Pharmac […]